Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial

被引：0

作者：

Gustavo, Federico

Todo, Rojo

Meier, Lara

Martinez, Maria Teresa

Lopez, Maria Esteban

Paris, Lorena

O'Connor, Miriam

Merino, Luis De la Cruz

Santaballa, Ana

Martinez-Janez, Noelia

Anton, Fernando Moreno

Fernandez, Isaura

Keane, Maccon

Garcia-Palomo, Andres

Starus, Anna

Portela, Marta

Herranz, Jesus

Caballero, Rosalia

Jones, Frederick

Albanell, Joan

机构：

[1] Hosp Univ Fdn Jimenez Diaz, Barcelona, Spain

[2] CIBERONC ISCCIII, Barcelona, Spain

[3] GEICAM Spanish Breast Canc Grp, Barcelona, Spain

[4] Sysmex Inostics Gmbh, Hamburg, Germany

[5] Hosp Clin Univ Valencia, INCLIVA, Valencia, Spain

[6] GEICAM Spanish Breast Canc Grp, Valencia, Spain

[7] Sysmex Inostics Inc, Hamburg, Germany

[8] Ctr Oncol Galicia, La Coruna, Spain

[9] GEICAM Spanish Breast Canc Grp, La Coruna, Spain

[10] Univ Hosp Waterford Canc Trials Ireland, Waterford, Ireland

[11] Univ Seville, Hosp Univ Virgen Macarena, Dept Med, Med Oncol, Seville, Spain

[12] Hosp Univ & Politecn La Fe, Dept Med Oncol, Valencia, Spain

[13] Raman y Cajal Univ Hosp, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Madrid, Spain

[14] Hosp Clin Univ San Carlos, Madrid, Spain

[15] GEICAM Spanish Breast Canc Grp, Madrid, Spain

[16] Hosp Alvaro Cunqueiro, Vigo, Spain

[17] GEICAM Spanish Breast Canc Grp, Vigo, Spain

[18] Hopsital Univ Son Espases, Palma de Mallorca, Spain

[19] GEICAM Spanish Breast Canc Grp, Palma de Mallorca, Spain

[20] Galway Univ Hosp, CIBERONC ISCIII, Galway, Ireland

[21] Complejo Asistencial Univ Leon, Leon, Spain

[22] GEICAM Spanish Breast Canc Grp, Leon, Spain

[23] Sysmex Inostics Inc, Baltimore, MD USA

[24] GEICAM Spanish Breast Canc Grp, Madrid, Spain

[25] Hosp Mar, CIBERONC ISCIII, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1029

引用

页数：1

共 34 条

[21] PIK3CA mutation testing prevalence among post-menopausal (PM) women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) using real world data
Princic, Nicole
Said, Qayyim
Smith, David
Johnson, William
Aizer, Ayal
CANCER RESEARCH, 2020, 80 (04)
[22] Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course
Bhave, Manali A.
Quintanilha, Julia
Ross, Jeffrey S.
Graf, Ryon P.
Levy, Mia Alyce
Kalinsky, Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)-GeparPiPPa
Loibl, S.
Reinisch, M.
Denkert, C.
Fasching, P. A.
Seiler, S.
Link, T.
Hanusch, C.
Bjelic-Radisic, V.
Schneeweiss, A.
Huober, J.
Jackisch, C.
Rhiem, K. E.
Untch, M.
Solbach, C.
Blohmer, J-U.
Buechele, T.
Nekljudova, V.
Loi, S.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S627 - S627
[24] PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR plus )/human endocrine receptor negative (HER2-) metastatic breast cancer (mBC): A meta-analysis of published clinical trials.
Signorovitch, James
Andre, Fabrice
Wang, Ruchuan
Lorenzo, Ines
Ridolfi, Antonia
Park, Jinhee
Fillbrunn, Mirko
Dua, Akanksha
Rugo, Hope S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] A phase I/Ib study evaluating GDC-0077+palbociclib (palbo) plus fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
Bedard, Philippe L.
Jhaveri, Komal
Cervantes, Andres
Gambardella, Valentina
Hamilton, Erika
Italiano, Antoine
Kalinsky, Kevin
Krop, Ian E.
Oliveira, Mafalda
Saura, Cristina
Schmid, Peter
Turner, Nicolas
Varga, Andrea
Hutchinson, Katherine E.
Lei, Guiyuan
Royer-Joo, Stephanie
Thomas, Piia
Schutzman, Jennifer L.
Juric, Dejan
CANCER RESEARCH, 2021, 81 (04)
[26] GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)
Loibl, Sibylle
Reinisch, Mattea
Denkert, Carsten
Schneeweiss, Andreas
Seiler, Sabine
Fasching, Peter Andreas
Hanusch, Claus
Link, Theresa
Bjelic-Radisic, Vesna
Huober, Jens
Untch, Michael
Jackisch, Christian
Solbach, Christine
Blohmer, Jens-Uwe
Rhiem, Kerstin
Buechele, Thomas
Nekljudova, Valentina
Loi, Sherene
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 38 - 39
[27] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
Turner, Nicolas
Jhaveri, Komal
Kalinsky, Kevin
Loibl, Sibylle
Loi, Sherene
Im, Seock-Ah
Saura, Cristina
Schmid, Peter
Schutzman, Jennifer L.
Stout, Thomas J.
Lei, Guiyuan
Hutchinson, Katherine E.
Thanopoulou, Eirini
Juric, Dejan
CANCER RESEARCH, 2021, 81 (04)
[28] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
Turner, N.
Jhaveri, K.
Kalinsky, K.
Loibl, S.
Loi, S.
Im, S-A.
Saura, C.
Schmid, P.
Schutzman, J. L.
Stout, T.
Lei, G.
Hutchinson, K. E.
Thanopoulou, E.
Juric, D.
ANNALS OF ONCOLOGY, 2020, 31 : S391 - S392
[29] Prospective testing for PIK3CA/AKT1/PTEN alterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2-BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial
Savage, Heidi
Lin, Wendy
Oliveira, Mafalda
Barrios, Carlos
O'Shaughnessy, Joyce
Turner, Nicholas
Dent, Rebecca
Isakoff, Steven J.
Saji, Shigehira
Lian, Qinshu
Bradley, Denise
Reilly, Sarah-Jayne
Hinton, Heather
Wongchenko, Matthew J.
Mani, Aruna
Kim, Sung-Bae
CANCER RESEARCH, 2021, 81 (04)
[30] PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2-advanced breast cancer (BC): First results from the randomized, phase Ill BELLE-2 trial
Baselga, J.
Im, S-A
Iwata, H.
Clemons, M.
Ito, Y.
Awada, A.
Chia, S.
Jagiello-Gruszfeld, A.
Pistilli, B.
Tseng, L-M
Hurvitz, S.
Masuda, N.
Cortes, J.
De Laurentiis, M.
Arteaga, C. L.
Jiang, Z.
Jonat, W.
Hachemi, S.
Le Mouhaer, S.
Di Tomaso, E.
Urban, P.
Massacesi, C.
Campone, M.
CANCER RESEARCH, 2016, 76

← 1 2 3 4 →